The global neurodegenerative disease market was valued at approximately USD 59.06 billion in 2025 and is projected to reach USD 83.37 billion by 2030, reflecting a compound annual growth rate of 7.14% during this period. Currently, there are no FDA-approved treatments specifically targeting tau or TDP-43 pathologies, which are implicated in all major neurodegenerative diseases. The development of a novel small molecule targeting these proteins presents a significant opportunity to address this unmet medical need. Such a therapeutic could potentially qualify for orphan drug designation, expediting clinical development and regulatory approval, particularly for conditions like FTD and ALS. Moreover, the mechanism of action of this small molecule offers the potential for expansion into other neurodegenerative indications, thereby broadening its therapeutic application and market reach.